The Journal of Allergy and Clinical Immunology
Volume 121, Issue 6 , Pages 1400-1406.e4, June 2008

The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: Implications for airway remodeling in asthma

  • Ilaria Puxeddu, MD, PhD

      Affiliations

    • Division of Infection, Inflammation, and Repair, School of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom
    • These authors contributed equally to this article.
  • ,
  • Yun Yun Pang, PhD

      Affiliations

    • Division of Infection, Inflammation, and Repair, School of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom
    • These authors contributed equally to this article.
  • ,
  • Anna Harvey, BSc

      Affiliations

    • Division of Infection, Inflammation, and Repair, School of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom
  • ,
  • Hans Michael Haitchi, MD

      Affiliations

    • Division of Infection, Inflammation, and Repair, School of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom
  • ,
  • Ben Nicholas, PhD

      Affiliations

    • Division of Infection, Inflammation, and Repair, School of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom
  • ,
  • Hajime Yoshisue, PhD

      Affiliations

    • Division of Infection, Inflammation, and Repair, School of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom
  • ,
  • Domenico Ribatti, MD

      Affiliations

    • Department of Anatomy, Faculty of Medicine, University of Bari, Bari, Italy
  • ,
  • Geraldine Clough, PhD

      Affiliations

    • Division of Infection, Inflammation, and Repair, School of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom
  • ,
  • Rob M. Powell, PhD

      Affiliations

    • Division of Infection, Inflammation, and Repair, School of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom
  • ,
  • Gillian Murphy, PhD

      Affiliations

    • Department of Oncology, University of Cambridge, Cambridge, United Kingdom
  • ,
  • Neil A. Hanley, MD

      Affiliations

    • Division of Human Genetics, School of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom
  • ,
  • David I. Wilson, MD

      Affiliations

    • Division of Human Genetics, School of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom
  • ,
  • Peter H. Howarth, MD

      Affiliations

    • Division of Infection, Inflammation, and Repair, School of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom
  • ,
  • Stephen T. Holgate, DSc

      Affiliations

    • Division of Infection, Inflammation, and Repair, School of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom
  • ,
  • Donna E. Davies, PhD

      Affiliations

    • Division of Infection, Inflammation, and Repair, School of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom
    • Corresponding Author InformationReprint requests: Donna E. Davies, PhD, Mailpoint 810, Southampton General Hospital, Southampton, SO16 6YD, United Kingdom.

Received 2 November 2007; received in revised form 12 February 2008; accepted 5 March 2008. published online 14 April 2008.

Background

A disintegrin and metalloprotease (ADAM)–33 is a susceptibility gene for asthma and chronic obstructive pulmonary disease whose function remains unknown.

Objective

Because asthmatic bronchoalveolar lavage fluid contains high levels of soluble ADAM33 (sADAM33), which includes the catalytic domain, we postulated that its release from cell membranes might play functional roles in airway remodeling by promoting angiogenesis.

Methods

The proangiogenic activity of the highly purified catalytic domain of ADAM33 or a catalytically inactive mutant was studied in vitro (Matrigel assay), ex vivo (human embryonic/fetal lung explants) and in vivo (chorioallantoic membrane assay). The regulation of sADAM33 release from cells overexpressing full-length ADAM33 and its biological activity were characterized.

Results

We show that the purified catalytic domain of ADAM33, but not its inactive mutant, causes rapid induction of endothelial cell differentiation in vitro, and neovascularization ex vivo and in vivo. We also show that TGF-β2 enhances sADAM33 release from cells overexpressing full-length ADAM33 and that this truncated form is biologically active.

Conclusion

The discovery that sADAM33 promotes angiogenesis defines it as a tissue remodeling gene with potential to affect airflow obstruction and lung function independently of inflammation. As TGF-β2 enhances sADAM33 release, environmental factors that cause epithelial damage may synergize with ADAM33 in asthma pathogenesis, resulting in a disease-related gain of function. This highlights the potential for interplay between genetic and environmental factors in this complex disease.

Key words: ADAM33, asthma, angiogenesis, airway remodeling

Abbreviations used: ADAM, A disintegrin and metalloprotease, BALF, Bronchoalveolar lavage fluid, CAM, Chick embryo chorioallantoic membrane, CHO, Chinese hamster ovary, COPD, Chronic obstructive pulmonary disease, FGF, Fibroblast growth factor, HEK, Human embryonic kidney, HUVEC, Human umbilical vein endothelial cell, SNP, Single nucleotide polymorphism, sADAM33, Soluble a disintegrin and metalloprotease 33, UK, United Kingdom, VEGF, Vascular endothelial growth factor

 

 Supported by the Medical Research Council UK; the Rayne Foundation; the British Lung Foundation; the Asthma, Allergy, and Inflammation Research Charity; the Roger Brooke Charitable Trust; and the Wellcome Trust. S.T.H. is supported by a Medical Research Council Clinical Professorship. I.P. was supported by a European Respiratory Society Short Term Traveling Fellowship and a European Academy of Allergy and Clinical Immunology Fellowship.

 Disclosure of potential conflict of interest: G. Clough has received research support from the British Heart Foundation, Unilever, and Probe Scientific UK. N. Hanley has received research support from Novo Nordisk. D. I. Wilson has received research support from the British Heart Foundation and the Department of Health UK. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(08)00553-8

doi:10.1016/j.jaci.2008.03.003

The Journal of Allergy and Clinical Immunology
Volume 121, Issue 6 , Pages 1400-1406.e4, June 2008